Chris Carroll BA, MA (King's College London), MSc (Sheffield), PhD (Cantab.)


Reader in Systematic Review and Evidence Synthesis

The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA

Office: 2020

Tel: (+44) (0)114 222 0864
Fax: (+44) (0)114 222 0749


ORCiD: 0000-0002-6361-6182


My BA, MA and PhD were in History, but I completed a vocational MSc in Information Science at Sheffield in 2003 and joined ScHARR in 2004 to work on a project funded by the Social Care Institute for Excellence (SCIE). During that time I completed two postgraduate modules on systematic review and critical appraisal methods. I then worked as a Research Associate for two years before joining HEDS as a Research Fellow in Systematic Review in 2007, and started work as a Senior Lecturer and Course Director of the MSc in International Health Technology Assessment, Pricing and Reimbursement (iHTA) in early 2011. I was promoted to Reader in 2014 and made a University Senate Fellow for Excellence in Learning and Teaching. I stepped down as Course Director of the iHTA programme in 2015 and have returned to working for the ScHARR Technology Assessment Group (TAG) conducting appraisals for NICE. 

Research interests

  • Systematic review and evidence synthesis of medical, health and social science topics, including qualitative and mixed method evidence synthesis
  • The Health Technology Assessment (HTA) process
  • Information retrieval and programme evaluation (implementation fidelity) research

Teaching Interests

  • Systematic review and evidence synthesis techniques
  • International Health Technology Assessment (HTA)
  • I am interested in supervising research students in topics/areas such as systematic review and evidence synthesis methods, the health technology assessment (HTA) process, and implementation research.

Current projects

  • NICE MTA (IP1553): Risk of transmission via surgical interventional procedures of Creutzfeldt-Jakob disease (CJD) (PI: M Stevenson).
  • NICE STA: (ID991): Regorafenib for previously treated unresectable hepatocellular carcinoma (PI: M Stevenson)
  • NICE MTA: (ID56): Cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer (PI: P Tappenden)

Professional Activities

  • Member of the NICE Interventional Procedures Advisory Committee (IPAC) 2014-

Extended list of publications

Journal articles